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Background: The hypoxic environment of tumor region stimulated the up regulation of growth factors responsible
for angiogenesis and tumor proliferation. Thus, targeting the tumor vasculature along with the proliferation by dual
tyrosine kinase inhibitor may be the efficient way of treating advanced breast cancers, which can be further
enhanced by combining with radiotherapy. However, the effectiveness of radiotherapy may be severely
compromised by toxicities and tumor resistance due to radiation-induced adaptive response contributing to
recurrence and metastases of breast cancer. The rational of using ZD6474 is to evaluate the feasibility and efficacy
of combined VEGFR2 and EGFR targeting with concurrent targeted and localized UV-B phototherapy in vitro breast
cancer cells with the anticipation to cure skin lesions infiltrated with breast cancer cells.
Materials and methods: Breast cancer cells were exposed to UV-B and ZD6474 and the cell viability, apoptosis,
invasion and motility studies were conducted for the combinatorial effect. Graphs and statistical analyses were
performed using Graph Pad Prism 5.0.
Results: ZD6474 and UV-B decreased cell viability in breast cancers in combinatorial manner without affecting the
normal human mammary epithelial cells. ZD6474 inhibited cyclin E expression and induced p53 expression when
combined with UV-B. It activated stress induced mitochondrial pathway by inducing translocation of bax and
cytochrome-c. The combination of ZD6474 with UV-B vs. either agent alone also more potently down-regulated the
anti-apoptotic bcl-2 protein, up-regulated pro-apoptotic signaling events involving expression of bax, activation of
caspase-3 and caspase-7 proteins, and induced poly (ADP-ribose) polymerase resulting in apoptosis. ZD6474
combined with UV-B inhibited invasion of breast cancer cells in vitro as compared to either single agent, indicating
a potential involvement of pro-angiogenic growth factors in regulating the altered expression and reorganization of
cytoskeletal proteins in combinatorial treated breast cancer cells. Involvement of combination therapy in reducing
the expression of matrix metalloprotease was also observed.
Conclusions: Collectively, our studies indicate that incorporating an anti-EGFR plus VEGFR strategy (ZD6474) with
phototherapy (UV-B), an alternative approach to the ongoing conventional radiotherapy for the treatment of infiltrating
metastatic breast cancer cells in the skin and for locally recurrence breast cancer than either approach alone.
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Conventional radiotherapy (RT) using X-rays and γ-rays
is used for the treatment of cancers and may be used as
primary or in adjuvant settings. Treatment with radi-
ation after breast cancer surgery as well as combined
treatment of radiation and chemotherapy is anticipated
to improve cancer treatment. Previous studies showed
that adding radiation to breast cancer treatment doesn’t
just lower a woman’s risk of having a relapse, it also im-
proves survival [1]. However, radiation is related to po-
tentially serious side effects including ischemic heart
disease and pneumonitis, sterility [2-4]. Moreover radio-
therapy led to development of radiation-induced adap-
tive response that contributes recurrence and metastases
of breast cancer by upregulating Epidermal growth
factor (EGF) receptor (EGFR) and vascular endothelial
growth factor (VEGF) receptor (VEGFR) related proteins
[5,6]. This led to the development of alternative form of
RT, popularly known as phototherapy. It is based on the
old concept of transfer of light energy or photons to
form intermediates, which resulted in the consumption
of oxygen. This reaction resulted in the formation of
singlet oxygen or reactive oxygen species (ROS). These
ROS are extremely toxic and have very short half-life,
thus affecting the adjacent cells without affecting the
surrounding tissues. Ultraviolet radiation mainly UV-B
(290–320 nm) having ~ 4 eV energy will be sufficient to
perform chemical reactions either forming DNA photo-
adducts or ROS [7]. UV-B phototherapy is widely used
for treating various skin disorders with minimal systemic
toxicities and side effects [8]. Though UV-B has its limi-
tation in reaching to the deeper tissues and organs, but
the development of LASER technology along with fiber
optic catheters guided by non-invasive imaging techniques
e.g., Magnetic resonance imaging, ultrasound imaging
makes feasible for the interstitial UV-B phototherapy to
act in periphery as well deep tissues and organs harboring
the tumor cells. In order to achieve the selective destruc-
tion of the target area, tumor specific photosensitizers
are either applied locally or intravenously where light
can be applied over the accumulated photosensitizers/
UV-sensitizers using minimally invasive fiber optic cathe-
ters guided by imaging devices. DNA being the intrinsic
UV-photosensitizers can form photo-adducts and pyrimi-
dine dimers by the introduction of UV-B radiation, which
generally halted the cell cycle progression in the S phase
of the cell cycle and induced apoptosis. The dual selectiv-
ity of phototherapy due to preferential localization of pho-
tosensitizers [9] or UV sensitizers [10] only to malignant
tissues, and restriction of photo-activation only in the li-
mited zone of irradiation makes it an alternative therapy
to pre-existing conventional RT. This phototherapy is con-
sidered as more targeted to destroy cancer cells or patho-
gens and less toxic to surrounding normal tissues than theconventional radiotherapy using ionizing radiation. To
investigate the effects of UV-B phototherapy on breast
cancer, we constructed a model in which cultivated
breast cancer cells were exposed to different doses of
UV-B radiation. UV-B radiation induces DNA photoprod-
ucts, such as pyrimidine dimers and (6–4) photoproducts
[11,12]. Ionizing irradiation produces double- and single-
strand DNA breaks. Cells respond to DNA photoproducts
and DNA breaks by accumulation of functionally active
p53 protein, a key event in response to cellular stress. The
signaling pathways that trigger a cell to undergo apoptosis
or alter the proliferation in response to UV radiation are
not well understood. UV radiation activates p53, cell death
receptor, ROS and induces mitochondrial release of
cytochrome-c, leading to apoptosis [13,14]. Most of the
clinical settings of UV-B used in treatment of skin disor-
ders are principally based on the effect of UV-B on apop-
totic effects of the irradiated cells.
RT alone, however, has not yielded ideal clinical out-
come and it is often associated with increased production
of EGF and VEGF that contributes to radio-resistance
[15] by activating growth factor mediated pathways in
squamous and mammary carcinoma cells [16-18]. Radi-
ation exposure activates mitogen activated protein ki-
nase (MAPK) pathway to a level similar to that observed
by physiological growth stimulatory, EGF concentra-
tions [16,17,19]. MAPK signaling has also been linked
to increased expression of growth factors such as EGF,
VEGF and transforming growth factor alpha (TGFα),
leading to increased proliferative rate of surviving cells
[20-22]. Growth factors such as VEGF and TGFα, in
addition to a growth-promoting role in vitro, may also
play an important role in the development of tumors
in vivo due to their abilities in the promotion of angio-
genesis. Like RT, UV radiation also activates VEGF sig-
naling involving EGF/PI3K pathway, activates invasion
by activating metalloproteinase [23-25]. Collectively,
these findings argue that UV-B phototherapy may have
a self-limiting effect on its toxicity via increased activity
of EGFR and VEGFR and downstream signaling mole-
cules such as the MAPK pathway. Thus, one interesting
and promising research direction for improving the treat-
ment of breast cancer could be a molecular-targeted
therapy against EGFR and VEGFR in association with
UV-B phototherapy.
Several studies demonstrate that the expression of
EGF and EGFR is related with breast cancer growth,
progression and aggressiveness and its overexpression is
an indicative of poor prognosis [26,27]. VEGF is closely
associated with the promotion of angiogenesis, incre-
ment of micro-vessel density and with early relapse in
primary breast cancer [28], yet clinical trials of agents
that target either EGF or VEGF signaling pathways alone
have been disappointing. Some tumors may not respond
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EGFR inhibitors. We hypothesized that targeting both the
tumor and its vasculature by VEGF- and EGF-receptor
(VEGFR, EGFR) blockade would improve breast cancer
treatment and provide wider applicability particularly
when combined with UV-B phototherapy. To test this
hypothesis, we evaluated the feasibility of combining
ZD6474, a dual tyrosine kinase inhibitor of VEGFR and
EGFR [29-32], with UV-B radiation in breast cancer cell
lines MCF-7, MDA-MB-231, MDA-MB-468 and T-47D.
This preclinical work was undertaken to serve as a ratio-
nale to support the role of ZD6474 in the treatment of
skin lesions infiltrated with metastatic breast cancer cells
and also for the recurrence breast cancer with UV-B
phototherapy, a promising treatment alternative to RT.
Results
Radiation (UV-B) suppresses cell viability of breast
cancer cells
VEGF level was measured by using VEGF ELISA kit. The
VEGF content of MCF-7, ZR-75-1, MDA-MB-231, MDA-
MB-468 and T-47D was found to be 297.91 ± 32.62,
493.32 ± 33.31, 1829.11 ± 50.01, 1429.51 ± 40.01 and
948.21 ± 20.11 ng/ml respectively per 106 cells (Figure 1A).
The VEGF content of normal human mammary epithelialFigure 1 Effect of radiation (UV-B) and ZD6474 is influenced by VEGF
CM for 48 h and VEGF was quantified by using ELISA. ** (p < 0.01), and ***
performing un-paired t-tests between HMEpC and different breast cancer c
treated breast cancer cells along with normal mammary HMEpC cells as an
growth inhibition of breast cancer cells MCF-7, MDA-MB-468 and HMEpC b
assay after 48 h of post treatment. Points, mean ± S. E. of three different excells (HMEpC) was 110.00 ± 11.12 ng/ml, and is signifi-
cantly lower than the breast cancer cells (MDA-MB-231
and MDA-MB-468). To compare the effect of UV-B on cell
viability of breast cancer cells in vitro, MCF-7, ZR-75-1,
MDA-MB-468, MDA-MB-231 and T-47D, and normal
mammary epithelial HMEpC cells were treated with in-
creasing doses of UV-B radiation (1–200 J/m2) and incu-
bated in culture medium for 2 days. UV-B reduced cell
viability in a dose-dependent manner and the cell growth
inhibition was prominent mainly between UV-B doses of
10–100 J/m2 (Figure 1B). The IC50 values of UV-B irradi-
ated MCF-7, ZR-75-1 MDA-MB-468, MDA-MB-231, and
T-47D cells were 101.20 ± 3.86, 74.21 ± 4.01, 32.54 ± 2.67,
35.33 ± 1.23, and 42.12 ± 2.12 J/m2 respectively (Table 1),
where as IC50 was found to be higher (>250 J/m
2) as par as
HMEpC was concerned. The VEGF level of MCF-7 is low-
est among the cell lines but IC50 of UV-B in MCF-7 was
found to be highest. MDA-MB-231 and MDA-MB-468
have highest level of VEGF (Figure 1A) and they were
shown to be more radiosensitive to UV-B. Moreover the
VEGF content of HMEpC is very less and hence showed
reduced sensitivity towards UV-B mediated cell killing, in-
dicating the role of UV-B phototherapy may be an alterna-
tive substitute for conventional radiotherapy. Based on the
sensitivity to UV-B, we have chosen two cancer cell linescontent in breast cancer cells. (A) Cells were grown in serum-free
(p < 0.001) indicates the increasing level of significance after
ells. Dose–response curve of (B) UV-B irradiated and (C) ZD-6474
alyzed by MTT assay after 48 h of post treatment. (D) Dose-dependent
y UV-B radiation in combination with ZD6474 as analyzed by MTT
periments each performed in quadruplicate.
Table 1 ZD6474 potentiates UV-B action on breast
cancer cells
Cell line Treatment regimen IC50 (J/m
2) PFa
MCF-7 UV-B 101.20 ± 3.86
UV-B + ZD6474 59.20 ± 2.45 1.71
ZR-75-1 UV-B 74.21 ± 4.01
UV-B + ZD6474 41.26 ± 3.01 1.80
MDA-MB-468 UV-B 32.54 ± 2.67
UV-B + ZD6474 12.17 ± 2.49 2.67
MDA-MB-231 UV-B 35.33 ± 1.23
UV-B + ZD6474 15.12 ± 2.12 2.34
T-47D UV-B 42.12 ± 2.12
UV-B + ZD6474 25.21 ± 2.12 1.67
HMEpC UV-B 250.72 ± 9.12
UV-B + ZD6474 248.12 1.01
aPotentiation Factor (PF) indicates a quantitative measure of fold-sensitivity of
UV-B radiation treated with 1 μM ZD6474 at a given effect compared with the
sensitivity of UV-B alone.
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MDA-MB-468 (most sensitive) to study the potentiating
effect of UV-B influenced by ZD6474.
ZD6474 in combination with UV-B cooperatively inhibits
growth in vitro
To evaluate potential cooperative interactions between
dual tyrosine kinase inhibitor (TKI)-ZD6474 and UV-B
(phototherapy), it was also necessary to study a dose re-
sponse curve of ZD6474 in breast cancer cells. It was
found that ZD6474 executed lesser toxicity in normal
HMEpC as compared to breast cancer cells (Figure 1C).
Thus it is anticipated that combinatorial effect of ZD6474
and UV-B will result in more efficient killing in breast
cancer cells with minimal effect in normal breast epithelial
cells. As a proof of principal, cells were treated with in-
creasing doses of UV-B followed by treatment with 1 or 5
or 10 μM ZD6474. The effect of dual TKI-ZD6474 with
UV-B showed combinatorial benefit. Treatment with
ZD6474 in combination with UV-B resulted a leftward
shift of the dose response curves (Figure 1D), indicating a
greater cytotoxic effect. As the concentration of ZD6474
increases, there was further shift of dose response curves
of UV-B radiation compared with combined effect of
1 μM ZD6474 and UV-B radiation. ZD6474 of 1 μM con-
centration potentiated the effect of UV-B radiation by
more than 1.5-fold in all breast cancer cell lines (Table 1).
There was > 75% cell viability when MCF-7 and MDA-
MB-468 cells were treated with 5 μM ZD6474 alone. The
decrease in cell number as well as the increase in cell
death (apoptosis) was prominent at 100 J/m2 and 50 J/m2
in MCF-7 and MDA-MB-468 irradiated with UV-B
alone. The radiation doses was further reduced to 50
and 25 J/m2 in MCF-7 and MDA-MB-468 respectivelywhen 5 μM ZD6474 was added as combined treatment
strategy to obtain the effect that was seen at higher radi-
ation doses (Additional file 1: Figure S1). When breast
cancer cells were treated with 10 μM ZD6474, the dose re-
sponse curve showed lesser leftward shift indicating lesser
synergistic or combinatorial effect which was expected as
the dose of ZD6474 above the sublethal dose, a prime fac-
tor for any combinatorial therapy in cancer treatment.
The most striking observation was there was no combina-
torial effect observed in normal HMEpC (Figure 1D), fur-
ther indicating the importance of combinatorial therapy in
the cancer management.
ZD6474 inhibits cell proliferation and induces apoptosis
in combination with UV-B
Cell viability is a dynamic process that reflects a balance
between cell proliferation and cell death. To define the
contributory roles of proliferation and apoptosis in cell
viability, Trypan blue dye exclusion tests and apoptosis
based flow-cytometric assays were performed. Decreased
cell viability was a consequence of both the growth in-
hibitory and apoptotic effects of ZD6474 when com-
bined with UV-B (Figure 2A). There was >30% apoptosis
in combinatorial-treated cells as compared to control
cells, which was further confirmed by flow-cytometry.
There were 30.2 ± 3.3, 43.3 ± 4.4% apoptosis in combin-
ation treatment as compared to 1.3 ± 0.5 and 1.4 ± 0.75%
in untreated control of MCF-7 and MDA-MB-468 re-
spectively. In contrast, there was less or no significant
apoptosis observed when cells were treated with either
agent alone (Figure 2A, 2B and 2C). Apoptosis was fur-
ther confirmed by observing under CLSM. Formation
of oligonucleosomes was easily recognized in MDA-
MB-468 cell lines following combination treatment
(Figure 2D). There was a prominent loss of cell mem-
brane asymmetry, attachment, membrane blebbing and
cytoplasm retraction, characteristic features of apop-
tosis, in combination treatment as compared to either
agent alone or untreated cells.
ZD6474 enhances the effect of UV-B in reducing
mitochondrial membrane potential (ΔΨm)
To see the involvement of mitochondrial membrane po-
tential (ΔΨm) in apoptosis induced by ZD6474 and/or
UV-B radiation, fluorescence intensity and shift was
monitored using potential-sensitive dye, rhodamine 123
(Rh-123) by flow-cytometry. In untreated control cells of
MDA-MB-468, ΔΨm showed high potential (Figure 3A,
and 3B). However, after 12 h of incubation with ZD6474
and/or UV-B, Rh-123 stained cells were separated into
two populations (M1; higher membrane potential, M2;
lower membrane potential) as shown in dot-plot and
histogram-plot by fluorescent strength (Figure 3A, and 3B).
There were 35.52 ± 5.87% and 45.93 ± 6.34% of MCF-7
Figure 2 ZD6474 enhances antiproliferative and apoptotic effects of UV-B radiation. (A) The combinatorial effect of ZD6474 (ZD) and UV-B
radiation in decreasing cell viability is attributed to both enhanced antiproliferative and apoptotic effects as shown by decreased cell counts by
Trypan blue dye exclusion tests. (B) MCF-7 and (C) MDA-MB-468 cells were treated with ZD6474 (ZD) and/or UV-B radiation, and stained with PI
for apoptosis measurements using flow-cytometry. The percentage of apoptotic cells is obtained by gating hypodiploid cells. (D) MDA-MB-468
cells were treated ZD and/or UV-B radiation and stained with DAPI, and observed under CLSM in confocal fluorescence (CF) mode and DIC mode
and the merged (CF + DIC) image. Red arrows; apoptotic nuclei, green dashed arrows; membrane blebbing, Arrow heads; intact nuclei. Bars;
10 μM. Representative figures of three independent experiments.
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ΔΨm in combined treatment of ZD6474 and UV-B
(Table 2). The reduction of ΔΨm was lower in ZD6474
treated cells as compared to the UV-B treated cells. In
order to examine the involvement of bax and cytochrome-
c translocation during this reduction in ΔΨm, mitochon-
drial fraction and cytosolic fraction of MDA-MB-468 cells
treated with ZD6474 and/or UV-B for 24 h were collected
and studied by western blotting. There was an evident
of translocation of bax from cytosol to mitochondrial in
UV-B irradiated MDA-MB-468 cells as the expression of
bax is increased in mitochondrial fraction and subse-
quently decreased in cytosolic fraction as compared to un-
treated control cell (Figure 3C). There was no significant
change of bax translocation in ZD6474 treated cells. But,
the addition of ZD6474 in UV-B treatment strategy pro-
foundly increased the expression of bax in mitochondrial
fraction as compared to either agent alone. There was also
change in expression of cytochrome-c in both subcellular
fractions, indicating the involvement of reduced ΔΨm
in association with cytochrome-c. Cytochrome-c was
significantly decreased in mitochondrial fraction andincreased in cytosolic fraction of cells treated with com-
bined ZD6474 and UV-B as compared to either agent
alone (Figure 3C), indicating its translocation from mito-
chondria to cytosol in combined treatment.
ZD6474 enhances the downstream activation of Caspase-
3 and Caspase-7 by UV-B radiation
To see the involvement of caspases downstream of mito-
chondrial pathway, casapse 3/7 activity assays of MCF-7
and MDA-MB-468 cells treated with ZD6474 and/or UV-
B for 48 h were performed using acetyl-Asp-Glu-Val-Asp
p-nitroanilide (Ac-DEVD-pNA) as the substrate. The rate
of decomposition of Ac-DEVD-pNA into p-nitroaniline
(pNA) reflects caspase-3/7 activation. The plateau of the
peak reflects the active form of caspase-3/7. The plateau
was significantly higher in combination treatment of
ZD6474 and UV-B in both MCF-7 and MDA-MB-468 as
compared to either agent alone or untreated control cells
(Figure 4A and 4B). The specific activity was calculated at
the linear region of enzyme kinetics (time vs. formation of
pNA) graph of caspase-3/7. In control untreated cells, the
activity was very less and there was a slight increase in
Figure 3 Loss of mitochondrial potential (ΔΨm) in ZD6474 and UV-B irradiated MDA-MB-468. Cells were stained with Rh-123 after
treatment with ZD6474 (Z) and/or UV-B radiation (R) along with untreated control (C). Top panel represented (A) dot plot of treated MDA-MB-
468. There was an evident change in ΔΨm in both MCF-7 and MDA-MB-468 in combination treatment as shown by the histogram plot
(B). Translocation of bax from cytosol to mitochondria vice versa for cytochrome-c translocation was observed in MDA-MB-468 in combination
treatment as confirmed by western blotting (C). COX-IV and α-tubulin was taken as loading control for mitochondrial and cytosolic
fraction respectively.
Table 2 Mitochondrial membrane potential (ΔΨm) of
ZD6474 and/or UV-B treated breast cancer cells
Cell line Treatment M1 (%)a M2 (%)b
MCF-7 Control 95.37 ± 2.45 4.62 ± 2.45
ZD6474 85.78 ± 3.16 14.22 ± 3.16
UVB 81.07 ± 3.64 18.93 ± 3.65
ZD6474 + UV-B 65.81 ± 3.89 35.52 ± 5.87
MDA-MB-468 Control 93.08 ± 1.36 6.92 ± 1.66
ZD6474 87.47 ± 1.04 12.53 ± 1.27
UVB 69.33 ± 2.92 30.66 ± 1.15
ZD6474 + UV-B 54.06 ± 5.08 45.93 ± 6.34
aPercentage (%) cells in M1 population was calculated by gating cells at higher
membrane potential. bPercentage (%) cells in M2 population was calculated by
gating cells at reduced membrane potential.
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The activity is significant when it irradiated UV-B alone,
but it is very significant when ZD6474 was added in the
treatment strategy of UV-B irradiated MCF-7 and MDA-
MB-468 (Figure 4C and 4D). Thus, ZD6474 enhances the
activity of UV-B radiation in the formation of active
caspases downstream of mitochondrial pathway.
ZD6474 alters cell regulatory proteins and apoptotic
proteins when used in combination with UV-B
To elucidate the molecular mechanism or the proteins in-
volved in enhanced activity of combination treatment of
ZD6474 and UV-B radiation, we sought to study both cell
regulatory and apoptotic proteins. There were marked de-
creases in Cyclin E expression in combination treatment
compared to control as well as cells treated with either
ZD6474 or UV-B radiation alone, whereas Cyclin E levels
were unchanged in cells treated with either agent as com-
pared to control. Though the change of p53 expression
was distinguishable in UV-B irradiated breast cancer
MCF-7 cells, but more significant changes in p53 levels
in combination treated breast cancer cells was observed
(Figure 4E). There was no change in expression of p53
in MDA-MB-468 (data not shown), but increased in
expression of p21 was noted in combined ZD6474 +
UV-B treated MDA-MB-468 cells (Figure 4F). Next weinvestigated the effect of single and combination treat-
ment on the expression of apoptotic proteins. Cleavage
of poly (ADP-ribose) Polymerase (PARP) was observed
in MCF-7 and MDA-MB-468 cells treated with either
of ZD6474 or UV-B as compared to control. The clea-
vage was more profound in combination treatment as there
was increased expression of the 85-Kd fragment (cleaved
PARP) with almost absence of the 116-Kd fragment
(uncleaved PARP). There was a decrease in anti-apoptotic
Figure 4 ZD6474 modulates UV-B action by altering the expression of caspases and apoptotic proteins. Time vs. pNA formation graphs
of (A) MCF-7 and (B) MDA-MB-468 treated ZD6474 (ZD) and/or UV-B radiation for 48 h was studied by monitoring the spectrophotometric
readings at 405 nm in order to study the Enzyme kinetics of caspase-3/7 using Ac-DEVD-pNA as substrate. Specific activity of Caspase-3/7 was
studied for (C) MCF-7 and (D) MDA-MB-468. Bars (mean ± S.E, n = 3), and * (p < 0.05), ** (p < 0.01) represent levels of significance with respect to
control. Western blotting of (E) MCF-7 and (F) MDA-MB-468 cells treated with ZD6474 (Z) and/or UV-B (R) for 48 h and probed with anti-PARP,
cyclin E, caspase-3, casapse-7, bcl-2, E-cadherin. β-actin protein expression was used as an internal probe for equal loading. Representative of
three independent experiments. Intact PARP, complete arrow; cleaved PARP, dashed arrow; block filled arrow, caspase-3 (MDA-MB-468).
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ticeable decrease of pro-caspase-3 in MDA-MB-468 fol-
lowing combination treatment, indicating the formation
of activated p11 and p17 caspase-3 in MDA-MB-468 cells
(Figure 4F). Caspase-3 is absent in MCF-7, indicating
a role of other effector caspases. There was decreased
expression in pro-caspase-7 (35-Kd) and increasedformation of active caspase-7 (20-Kd) in combination-
treated MCF-7 cells (Figure 4E).
ZD6474 inhibits cell migration when used in combination
with UV-B radiation
Tumor cell migration is a critical factor in the formation
of solid tumors and is necessary for their spread to distant
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adhesion, increased cell migration, and angiogenesis. To
determine the effect of ZD6474 and/or UV-B on migra-
tion, in vitro wound (scratch) assays were performed in
both MCF-7 and MDA-MB-468 cultures. The size of
the wound (scratch) before treatment was 487.60 ± 9.76
(mean ± S.E.), which was decreased to 180.37 ± 10.33,
228.00 ± 15.11, 227.00 ± 9.07 and 390.30 ± 25.36 for
control, ZD6474, UV-B and combined ZD6474 and
UV-B treatment in MCF-7 cells after 24 h post-
treatment. In the case of MDA-MB-468, the size of the
wound (scratch) prior to treatment was 568.70 ± 15.47,
which was decreased to 39.69 ± 10.69, 279.30 ± 25.12,
300.70 ± 18.32 and 529.80 ± 28.90 for control, ZD6474,
UV-B and combined ZD6474 and UV-B treatment, re-
spectively, 24 h post-treatment. These results showed
that ZD6474 in combination with UV-B effectively
blocked cell migration of MCF-7 and MDA-MB-468
cells (Figure 5A and 5B) and inhibited wound healing,
as there was no significant change in wound size of
both MCF-7 and MDA-MB-468 cells 48 h and 24 h
post-treatment respectively with the combination of
ZD6474 and UV-B as compared to the initial time of
treatment. The cell migration was more prominent in
MDA-MB-468 as compared to MCF-7 as the scratch
was almost completely filled after 24 h in MDA-MB-
468 as compared to 48 h post-treatment in MCF-7.
There was also significant change in wound size in
MDA-MB-468 cells after 12 h as compared to 24 h
post-treatment in MCF-7 (Figure 5C and 5D). Accor-
dingly, the EGFR and VEGFR-2-TKI ZD6474 may be an
effective tool in inhibiting tumor formation as well as
blocking breast cancer invasion and potentially metastasis.
Additionally, there was an increase in E-cadherin expres-
sion in MCF-7 and MDA-MB-468 cells after treatment
with either ZD6474 or UV-B (Figure 4E and 4F),
suggesting a role in cytoskeletal reorganization and
stabilization, but the decrease in expression of E-
cadherin in combination treatment may be a conse-
quence of induction of apoptosis. Next we investigated
the role of ZD6474 and/or UV-B radiation in the pro-
duction of VEGF, proangiogenic factor, responsible for
migration and invasion of breast cancer cells. VEGF se-
cretion in the serum-free culture conditioned medium
was measured using ELISA after 48 h post-treatment of
breast cancer cells with ZD6474 and/ or UV-B radi-
ation. It was found that ZD6474 inhibits VEGF secre-
tion by ~6-fold as compared to untreated MCF-7
(Figure 5E). Though there was upregulation of VEGF
secretion in MCF-7 irradiated UV-B, but the change
was not significant (p = 0.713, n = 3). It was found that
ZD6474 inhibited VEGF secretion significantly in UV-B
irradiated MCF-7 (p = 0.003) as compared untreated
MCF-7. There is also decrease in secretion of VEGF inZD6474 treated MDA-MB-468 as compared to un-
treated cells (p = 0.001), and the decrease is also signifi-
cant (p = 0.003) in combined ZD6474 + UV-B treated
MDA-MB-468 cells (Figure 5F).
ZD6474 in combination with UV-B induces cytoskeleton
reorganization in breast cancer cells
To understand and correlate the effects of ZD6474 and/
or UV-B in cell migration and motile phenotypes, we
used confocal laser scanning microscopy (CLSM) to
study cytoskeletal remodeling and generation of mem-
brane protrusions, such as pseudopodium, filipodia and
ruffle formation. ZD6474 lead to reorganization of F-
actin structure. Long stressed F-actin filaments were ob-
served across the cell in ZD6474 as compared to control
cells (Figure 6A). Stress fibers were not prominently vis-
ible in UV-B treated cells as compared to ZD6474. In
contrast, the combination of ZD6474 and UV-B pro-
duced F-actin rings exclusively in the perinuclear zone
and the contraction of cytoplasm, indicating apoptosis
was noticeable. ZD6474 and UV-B blocked membrane
protrusions, such as microspikes, filopodia and lamelli-
podia formation, which was almost absent in MCF-7
and MDA-MB-468 following combination treatment
with ZD6474 and UV-B (Figure 6A). The loss and dra-
matic collapse of cytoskelatal structure following com-
bination treatment may be a consequence of induction
of apoptosis. In the study of cancer therapy and invasion,
high resolution SEM is a vital tool for analysis of expres-
sion of microspikes like lamellipodia and fillipodia, a
cytoskeleton protein involved in the movement of cancer
cells. The ultra-structure of cells was observed by FE-
SEM. The images of untreated control MCF-7 and
MDA-MB-468 showed the appearance of lamellipodia
and fillipodia (Figure 6B) in consistent with previous re-
sults observed under CLSM. Interestingly, membrane
blebs, and apoptotic bodies were observed in combined
ZD6474 and UV-B, indicating apoptosis. Microspike-like
protrusions were reduced drastically in MCF-7 and
MDA-MB-468 cells treated with ZD6474, and it was
completely lost in combination treatment, reflecting the
enhanced activity of ZD6474 in reducing cell migration of
breast cancer cells irradiated with UV-B (Figure 6B). Next,
we investigated the effect of ZD6474 and UV-B on the se-
cretion of MMP-9, which is believed to play an important
role in tumor invasion. Zymographic analyses showed
ZD6474 inhibits Matrix metalloprotease (MMP-9) activity
(Figure 6C). Apart from its anti-EGF and VEGF effect in
inhibiting tumor cells, it can also inhibit metastasis and
spread of breast cancer cells by inhibiting MMP. Though
decrease in MMP-9 activity was observed in case of UV-B
irradiated cells, but it was not significant. The addition of
ZD6474 enhanced its anti-metastatic potential by > 2-fold
with respect to untreated control (Figure 6C).
Figure 5 ZD6474 inhibits migration in breast cancer cells in combination with UV-B by inhibiting VEGF signaling pathway. Scratching
across a cell monolayer on a 6-well culture plate created a wound and the width of the wound was recorded prior to treatment with ZD6474
and/or UV-B and after indicated h post-treatment. Photomicrograph of ZD6474 and/or UV-B treated (A) MCF-7 and (B) MDA-MB-468 cells after
48 h and 24 h post-treatment respectively. Scale bar, 100 μM. Bars, S.E., three random widths along the wound at indicated h post-treatment of
(C) MCF-7 and (D) MDA-MJ B-468 cells. P-values were calculated by using un-paired t-test of the same treatment groups (prior and after
stipulated h post-treatment). Breast cancer cells were treated with ZD6474 and/or UV-B and incubated in serum-free CM for 48 h. VEGF level of
(E) MCF-7 and (F) MDA-MB-468 was determined by ELISA. All data were derived from a minimum of three independent experiments using
different cell preparations. *P < 0.05, comparing levels of untreated control with treated cells.
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Figure 6 ZD6474 in combination with UV-B alters cytoskeleton organization and extracellular MMP-9. MCF-7 and MDA-MB-468 cells were
treated with ZD6474 (ZD) and/or UV-B for 24 h, and then were immunofluorescently labeled using fluorescently-labeled phalloidin (F-actin-binding
protein, green) and DAPI (DNA binding dye, blue). ZD and UV-B effectively blocked cell spreading lamellipodia (white arrow) and induced thick and
stress actin fiber (red dashed arrow), whereas combination treatment lead to contraction of cytoplasm and F-actin rings around the periphery of the
nucleus as observed under (A) CLSM (white filled arrow head). Bars, 10 μM. ZD blocked lamellipodia and filopodia formations (black arrow), which
when combined with UV-B lead to contraction of cytoplasm (black dashed arrow) and formation of membrane blebs and apoptotic bodies (white
filled arrow head) in addition with drastic loss of lamellipodia-like structures as evident from the photomicrograph of the surface of breast cancer cell
studied under under (B) scanning electron microscope (SEM). Bars, 10 μM. ZD6474 (ZD/Z) in combination with UV-B (R) effectively inhibits MMP-9
activity as evident from (C) Zymograph of CM of MCF-7 and MDA-MB-468 cells treated with ZD and/or UV-B.
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Locally advanced breast cancer constitutes 30-60% of
breast cancer cases and remains a clinical challenge as
the majority of patients with this diagnosis develop dis-
tant metastases despite appropriate and preexisting
radiotherapy and surgery [33]. Locally advanced breast
cancers are often associated with higher expression of
growth factors EGF, VEGF that are associated with
shorter relapse free survival or over-all survival and ag-
gressiveness of the disease [34,35]. Thus, there is a re-
quirement of developing non-toxic, more effective novel
therapeutic approach to combat this loco-regional recur-
rence of breast cancer, particularly for the patients
treated prior with RT. These studies were initiated to
further understand the role of VEGF with aggressive na-
ture of breast cancer cells in vitro. MDA-MB-231 and
MDA-MB-468 showed higher expression of VEGF and
are more aggressive as compared to T-47D and MCF-7,
least aggressive of the four cell lines. IC50 was > 40 J/m
2
in both MDA-MB-468 and MDA-MB-231 cells. IC50
was < 40 J/m2 in T-47D and the IC50 ~100 J/m
2 for
MCF-7 irradiated cells (Figure 1). It indicates that the
higher levels of VEGF in breast cancer cells in vitro are
more sensitive to phototherapy (UV-B), and the lesser
expression of VEGF will help in the normal mammary
endothelial cells to escape the UV-B phototherapy, an
important factor to consider for the safety of UV-B
phototherapy in breast cancer treatment. Previous find-
ings have shown that higher levels of EGF, VEGF and
their cognate receptors were found to be the predictor
of radio-response as compared to non-responders [34].
We observed similar findings with UV-B phototherapy.
Previously it was also noticed that UV induced DNA
damage resulting in cell death is dependent on nuclear
excision repair protein (NER) protein [36]. In order to
check the effect of UV-B radiation on nucleotide exci-
sion repair (NER) pathway, we have checked the level of
XPA and ERCC1 expression (Additional file 2: Figure
S2), and found that the sensitivity of UV-B in mediating
cell death doesn’t completely depend on the level of
NER pathway involved proteins i.e. XPA and ERCC1.
Thus, the additional pathway might be involved in UV-Bmediated cell death. It was shown that apart from DNA
damage induced cell death by UV-B, death receptor
pathway, decrease in mitochondrial potential (ΔΨm) and
ROS are also involved in cell death [14,37,38]. Moreover,
it was earlier reported that the “window “ of operating
NER pathway is confined to low doses of UV-B where as
at high doses of UV-B, NER involvement is not observed,
and the apoptotic mechanism dominates over NER path-
way [39]. To date, the pathways involving UV-B mediated
apoptosis is not well elucidated and interestingly we have
found a strong correlation of UV-B sensitivity and VEGF
expression in breast cancer cells. Considering also the fact
that UV-B lead to VEGF overexpression resulting in
radio-resistance, it prompted us to investigate the role of
anti-VEGF agent in sensitizing UV-B phototherapy medi-
ated apoptosis in breast cancer cells.
RT is effective modality of treatment widely used for
treating higher staging or locally advanced breast can-
cers [40]. Although widely used, a need remained to im-
prove the cure rate by RT alone. The treatment based on
chemotherapeutic agents paclitaxel, doxorubicin to RT
in non-operable and recurrent disease, was found to be
of good efficacy [41-43]. The cytotoxicity of chemothera-
peutic agents, however, is not limited to tumor cells be-
cause treatment of tumors with these agents can result in
significant normal tissue toxicity. Thus, the current thera-
peutic challenge is to optimize available non-operative
strategies by incorporating new non-cytotoxic agents into
current therapeutic regimens of RT. These led to the devel-
opment of antiangiogenic therapies or molecular targeted
therapies (Tyrosine kinase inhibitors) that target specific
receptors VEGFR in endothelium cells that forms capillar-
ies and supplies nutrients for hundreds of tumor cells.
Hence, targeting of the tumor vasculature should lead to a
potentiation of the antitumorigenic effect [44]. Some re-
cent preclinical studies suggest that the combination of RT
and angiogenic blockade enhances the therapeutic poten-
tial of ionizing radiation by targeting both tumor cells and
tumor vessels [45,46]. However, loco-regional recurrence
of breast cancer after surgery and post-operative RT occurs
around 10-20% and 5-8% respectively [25]. Thus, photo-
therapy utilizing the energy of photons in combination
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generate ROS or DNA damage in the tissue specific man-
ner seems to be a promising alternative for treatment of
advanced breast cancer patients for whom the RT is lim-
ited due to prior therapies. There is a recent development
of targeted phototherapy, photosensitizers [47,48] that fur-
ther minimizes the toxicities associated with UV photo-
therapy. Ionizing radiation enhances both epithelial growth
factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) expression, and similar results were
obtained with UV radiation [23,49], which are a part of
key pathways for tumor progression and radioresistance
[16]. It was also noticed that there was positive corre-
lation between VEGF expression and ZD6474 sensitivity
in decreasing cell proliferation as shown in Figure 1C.
Thus, it supports the rational of combining UV-B radi-
ation and ZD6474 in treating breast cancer cells. More-
over, it was found that 5-flurouracil, an anti-cancer drug
with ionizing radio-sensitization activity, also enhanced
the UV-B mediated apoptosis in breast cancer [50]. Pre-
viously it was shown that dual targeting of EGFR and
VEGFR in combination with RT enhanced antitumor ac-
tivity of lung cancer in vivo as compared to either agent
alone [51]. Considering these previous findings, it is likely
that EGFR and VEGFR-TKI ZD6474, when combined
with UV-B phototherapy, will improve tumor control and
provide wider applicability. The mechanisms by which
tumor response to UV-B radiation is enhanced by
ZD6474, however, are not currently understood.
In our study using in vitro breast cancer cells MCF-7
and MDA-MB-468 that closely recapitulates breast can-
cer with lower and higher VEGF expression respectively,
we found that ZD6474 substantially improved radio-
response to UV-B in both cell lines. The radio-sensitivity
to UV-B was > 2-fold in higher expressed VEGF produ-
cing MDA-MB-231 and MDA-MB-468 (Table 1) when
treated with 1 μM ZD6474 in combination with UV-B.
The mechanism underlying the decrease in cell viability
following combination treatment with ZD6474 and UV-
B was studied. The photomicrograph of MCF-7 and
MDA-MB-468 irradiated with increasing doses of UV-B
clearly demonstrated the involvement of apoptosis in de-
creasing cell viability (Figure 2) with lesser involvement
of antiproliferative effects, which was further confirmed
from cell counts using trypan blue dye exclusion assays.
It was shown earlier that UV radiation induced apop-
tosis as compared to ionizing radiation that mainly in-
duced cell cycle arrest in osteosarcoma in vitro [52].
Moreover the extent of DNA damage, cell type, and ge-
netic alterations determined the cells/tissues response to
radiation to undergo either apoptosis or cell cycle arrest.
Hence, the elucidation of the mechanism of UV-induced
apoptosis in breast cancer will be important to make a
rational decision for combining UV-B radiation withchemotherapeutic agents or small inhibitors e.g., TKI. In
contrast to UV-B, ZD6474 is more an antiproliferative
agent than a cytotoxic agent at its lower concentration
(<IC50). The enhanced activity of ZD6474 in decreasing
cell viability may be contributed both due to anti-
proliferative and apoptotic effects of combination treat-
ment (Figure 2). ZD6474 significantly potentiates the
apoptotic activity of UV-B as shown by flow-cytometry
(Figure 2). Formation of oligonucleosomes or fragmented
DNA, membrane blebbing further confirmed that cell
death was due to activation of the apoptotic pathway as
shown in Figure 4. Our findings have shown that ZD6474
may improve the therapeutic index for UV-B photothe-
rapy by enhancing tumor-specific cytotoxicity.
Non-cytokine-mediated cellular stress, such as UV or
chemical treatment, can initiate apoptosis through mito-
chondrial release of cytochrome-c [13]. There was a sig-
nificant change in mitochondrial membrane potential
(ΔΨm) that is associated with release of cytochrome-c in
cytosol, initiating the apoptotic pathway mediated by
mitochondria. There was also change in bax transloca-
tion (Figure 3), further implying the involvement of
mitochondria in stress signaling pathway induced by
UV-B radiation [53]. It was also found that ZD6474 in-
creased the active form of caspase-7 (effector caspase in
MCF-7 as it is deficient in caspase-3) in UV-B irradiated
cells. It was confirmed both by catalytic activity of
caspase-7 and protein expression observed by western
blotting. But the enhanced catalytic activity of ZD6474
induced UV-B irradiated MDA-MB-468 was found to be
associated with increased expression of active form of
casapse-3 (Figure 4). There was also a slight change in
caspase-7 activity (data not shown) in ZD6474 induced
UV-B irradiated MDA-MB-468 cells. These eventually
led to the formation of apoptosome, a multi-protein
complex containing cytochrome-c, Apaf-1, and pro-
caspase-9 and finally activation of effector caspase-3/7
leading to apoptosis [54].
The molecular mechanism involving the enhanced ac-
tivity of combination treatment was further investigated
by western blotting. There was a decrease in cyclin E
(Figure 4) expression following combination treatment
as compared to untreated control and exposure to single
agents alone, indicating cell cycle arrest at G1-S or syn-
thetic phase in UV-B irradiated cells. UV-B radiation in
presence of ZD6474 induced DNA damage irreparable
that ultimately arrested the irradiated cells at synthetic S
or G1-S phase of cell cycle [55]. There was a decrease in
expression of cyclin E in ZD6474 induced UV-B irra-
diated cells which is in agreement with our prior fin-
dings [56]. The alteration of both cyclin D1 and cyclin E
was associated with breast cancer progression, early re-
lapse, poor prognosis and chemo-resistance to various
cytotoxic agents [57-59]. There was an increase in
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protein in breast cancer cells treated with combined
ZD6474 and UV-B (Figure 4). The increase in p53 ex-
pression after cytotoxic insults was obvious, which is in
agreement with previous and recent findings [52,60].
Previous findings had shown that increase in p53 expres-
sion was mainly due to p53 stabilization in irradiated
cells as compared non-irradiated cells or cells capable of
DNA repair. It was also shown that there was more in-
creased expression of p53 in UV-B irradiated cells as
compared to X-ray irradiated cells, eventually leading to
more apoptosis in the former irradiated cells. Though
p53 level was unchanged in ZD6474 treated cells, but its
addition in the treatment strategy of UV-B irradiated
cells increased the cytotoxicity nature of the cells that
lead to further insults in DNA damages as evident in cell
viability and flow-cytometric assays which were in con-
sistent with higher expression of p53 in combination
treatment in wild type p53 MCF-7 cell line (Figure 4),
and no such change was associated with mutant p53
bearing MDA-MB-468. Previous findings had shown
that UV induced apoptosis via direct p53-E2F1-Bcl-2
pathway by downregulating Bcl-2 where as it can also
induced apoptosis in p53 independent manner via direct
effect of Bcl-2 regulation by pyrimidine dimers [61].
Thus, Bcl-2 might play an important role in UV-B induced
apoptosis. So, we checked the Bcl-2 expression in com-
bined therapy, and noticed that Bcl-2 was downregulated
by UV-B radiation in cell lines expressing wild type p53
(MCF-7) and its mutant form (MDA-MB-468), indicating
that UV-B induced apoptosis acts through both p53
dependent and independent pathways which is in agree-
ment with prior findings [61,62].
Cell migration and invasion are crucial steps in the
physiopathology of development of cancer and metasta-
sis [63,64]. ZD6474 inhibited motility of breast cancer
cells (Figure 5) that was further decreased when ZD6474
is combined with UV-B. It was found that 48 h was re-
quired to fill the scratch in MCF-7 as compared to 24 h
in MDA-MB-468, which is in agreement with previous
findings that MDA-MB-468 is more aggressive of the two
due to higher content of VEGF (chemotactic growth fac-
tors) in the former. We found that ZD6474 decreased
VEGF expression probably by downregulating PI3K path-
way [65] that contributes to downregulation of VEGF
transcription (Figure 5E, and 5F). Though not significant,
but an increased in VEGF level was observed in both cell
lines when treated with UV-B radiation. It might be due
to the fact that the cytotoxic effects induced by UV-B dose
that was used in the experiment inhibited VEGF expres-
sion probably. There are reports, which suggest that
UV radiation is an inducer of VEGF [23,66]. Thus the
addition of ZD6474 to UV-B radiation might be benefi-
cial in inhibiting its proangiogenic related activities.The decreased motility observed in these cells may
have an effect on cytoskeletal and cell adhesion mole-
cules induced by ZD6474. Motility depends on an or-
dered series of events that require cell polarization,
membrane extension into a lamellipodium, filipodium,
attachment of the leading edge to the substratum, trac-
tion by stress fibers formed from the leading edge, and
release of the lagging end of the cell. ZD6474 decreased
cellular lamellipodia and filopodia extrusions and re-
sulted in an almost complete loss of these projections in
combination treatment (Figure 6A, and 6B). ZD6474
also increased E-cadherin expression in both cell lines
(Figure 4E). Thus, ZD6474 stabilized cytoskeletal struc-
ture and inhibited invasion and migration of cancer cells.
This is consistent with earlier studies demonstrating that
intermediate levels of adherence are needed for optimal
migration and that increasing or decreasing adherence
actually decreases the rate of cell migration [67,68]. Loss
of actin organization is characteristic of many tumor
cells. Our results suggest that ZD6474 stabilized stress
actin filaments, characteristics of normal differentiated
cells. In case of UV-B irradiated cells, the change
was not significant but the combined treatment with
ZD6474 and UV-B led to disorganized actin filaments
due to increased apoptosis [69].
Conclusions
Collectively, our studies support a therapeutic approach for
loco-regional occurrence of breast cancer that includes
treatment with a dual EGFR- and VEGFR-targeted agent
plus UV-B phototherapy, particularly those for whom the
use of RT is limited by prior therapies. In addition to
inhibiting endothelial cell proliferation and angiogenesis by
blocking VEGF-induced signaling, ZD6474 also inhibited
cancer cell growth and induced apoptosis. ZD6474 en-
hanced UV-B action in inhibiting cell viability by inducing
apoptosis of breast cancer cells in vitro. ZD6474 modulated
the angiogenic properties of UV-B radiation. It also has the
potential to inhibit cell migration and metastases. Consi-
dering the fact that UV-B phototherapy is already being
practiced in clinics for skin lesions, and the preclinical
success of dual TKI in combination therapy with vari-
ous anti-cancer agents, these observations have consi-
derable potential clinical relevance for patients with
locally advanced breast cancer or skin lesions infiltrated
by malignant breast tumor.
Materials and methods
Cell lines
Human breast cancer cell lines MCF-7, MDA-MB-231
and MDA-MB-468 were cultured in Dulbecco’s Modified
Eagle’s Medium: Nutrient Mixture F-12 (Ham) (D-MEM/
F-12) with 15 mM HEPES buffer, L-glutamine, pyridoxine
hydrochloride, supplemented with 1.2 g Sodium bicarbonate
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penicillin and 10 mg/L streptomycin) (Himedia, Mumbai,
Maharashtra India) and 10% fetal bovine serum (FBS)
(Invitrogen, Grand Island, NY, USA). T-47D and ZR-751
cells were grown in RPMI-1640, supplemented with 10%
FBS. Human Mammary Epithelial Cells (HMEpC) (Cell
Applications, Inc., San Diego, CA, USA) and were grown
as per as manufacturer instructions. Cells were incubated
at 37°C in a 5% CO2 and 95% humidified incubator.Reagents
Stock solutions of 20 mM ZD6474 (AstraZeneca Pharma-
ceuticals, Macclesfield, United Kingdom) were dissolved
in DMSO (Sigma-Aldrich, St. Louis, MO, USA), stored
at −20°C, and diluted in fresh medium just before use.
For Western blot analysis, the following antibodies were
used: rabbit monoclonal anti-PARP, anti-E-cadherin, mouse
monoclonal anti-cyclin E, anti-caspase-3, (Cell Signaling
Technology, Beverly, MA, USA), mouse monoclonal
anti-caspase-7 (BD Pharmingen, Franklin Lakes, NJ,
USA), mouse monoclonal anti-β-actin (Sigma-Aldrich),
mouse polyclonal anti-bcl-2, anti-bax, anti-p53, horse-
radish peroxidase-conjugated goat anti-rabbit IgG and
goat anti-mouse IgG, alkaline phosphatase-conjugated
goat anti-rabbit IgG and goat anti-mouse IgG (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Chemilu-
minescent peroxidase substrate, BCIP/NBT, Propidium
iodide (PI), 4′,6-diamidino-2-phenylindole (DAPI) and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-
pNA), Gelatin A and Gelatin B (Sigma-Aldrich), and
Fluorescein phalloidin (Molecular Probes™, Invitrogen
Corporation, Eugene, Oregon) , were purchased from
the indicated company. Stock solutions of PI and DAPI
were prepared by dissolving 1 mg of each compound in
1 ml PBS and MTT in incomplete medium. The solu-
tion was protected from light, stored at 4°C, and used
within 1 month. Stock concentrations of 10 mg/ml
RNase A dissolved in water and 20 mM Ac-DEVD-
pNA (Sigma-Aldrich) dissolved in DMSO were pre-
pared and kept at −20°C.UV-B irradiation
For UV-B irradiation, the medium was removed from
cells grown in cell culture plates or in 96-well tissue be-
fore UV exposure. Cells were exposed to UV-B using a
UV cross-linker (Agilent Technologies, Inc., Stratagene,
Santa Clara, CA, USA) equipped with 598 W tubes
which emit most of their energy within the UV-B range
(290–320 nm) with an emission peak at 312 nm [70].
Control cells were treated similarly by the same proto-
col, except for radiation. After irradiation, cells were re-
incubated in culture medium with or without ZD6474.Evaluation of cytotoxicity of ZD6474 and/or UV-B
irradiation
Cells were harvested in the logarithmic phase of growth;
cell suspensions were dispensed (200 μl) into 96-well tis-
sue culture plates at an optimized concentration of 1 ×
104 cells/well in complete medium. 24 h after seeding,
cells were irradiated with UV-B (1–200 J/m2) after the
removal of the medium, and then reincubated for 48 h
in the medium with different concentration of ZD6474
along with control treatment (0.1% DMSO. Cell viability
was measured by MTT dye reduction assay at 540 nm.
The dose-effect curves were analyzed using Prism soft-
ware (GraphPad Prism 5.0, San Diego, CA, USA). For all
subsequent experiments 1 μM ZD6474 and 25 J/m2 UV-B
dose was selected, until otherwise mentioned.
Apoptosis measurement by flow-cytometry
To study the effect of combination treatment of ZD6474
and UV-B cells were irradiated with 25 J/m2 UV-B,
followed by treatment with 1 μM ZD6474 for 48 h after
seeding in 60-mm tissue culture plates. After treatment,
both attached and floating cells were collected and washed
in phosphate-buffered saline (PBS) and incubated in 70%
ethanol, kept at −20°C overnight for fixation. Cells were
centrifuged, washed and then incubated with PI solution
(40 μg/ml PI, 100 μg/ml RNase A in PBS) at 37°C for 1 h.
Apoptotic cells were determined by their hypochromic
sub-diploid staining profiles. The distribution of cells in
the different cell-cycle phases was analyzed from the DNA
histogram using Becton-Dickinson FACSCalibur flow-
cytometer and CellQuest software.
Measurement of mitochondrial membrane
potential (ΔΨm)
To measure mitochondrial transmembrane potential
(ΔΨm), rhodamine 123 (Rh-123) were used [71]. MCF-7
and MDA-MB-468 cells were treated with ZD6474 and/
or UV-B radiation for 12 h. After that cell were washed
with PBS, and were stained with Rh-123 at the final con-
centration of 5 μg/ml for 30 min at 37°C. Samples
stained with Rh-123 were subjected to flow-cytometry
(Becton Dickinson FACS Calibur flow-cytometer) (BD,
San Jose, CA, USA). The emission wavelength was
detected through the FL1 channel. Data were acquired
and analyzed with CellQuest software.
Preparation of cytosolic and mitochondrial extracts
Cytosolic and mitochondrial extracts were prepared as
described previously [72]. MCF-7 and MDA-MB-468
cells were seeded in 90-mm cell culture plates for 1 day,
and treated as indicated. Cells were then harvested and
washed in PBS. After spinning down, cells were re-
suspended in 100 μl of HED buffer (10 mM HEPES
pH 7.9, 10 mM Kcl, 0.1 mM EDTA pH 8, 1.0 mM
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1 mM phenylmethylsulfonyl fluoride (PMSF), protease
cocktail inhibitor), After incubation on ice for 20–
30 min, cell suspensions were vortexed for 10 sec for cell
lysis, followed by centrifugation at 5000 rpm for 5 min
at 4°C. Cytosolic protein (supernatant) was collected and
further centrifuged at 10000 rpm, 30 min to remove
crude membranes and to obtain a clear cytosolic fraction
free of membrane debris, and stored at −70°C. Mitochon-
drial extracts (cell pellet) were then washed with mitochon-
drial extraction buffer (10 mM HEPES pH 7.4, 200 mM
mannitol, 70 mM sucrose, 1 mM EGTA or EDTA pH 8,
1 mM DTT, 1 mM PMSF, protease cocktail inhibitor) to
remove any traces of cytosolic extract, and finally lysed
with 50 μl of mitochondrial extraction buffer on ice for
60 min with intermittent vortexing. Mitochondrial protein
was collected after centrifuging at 15,000 rpm for 30 min
at 4°C, aliquot and stored at −70°C.
Western blot analysis of growth regulatory proteins and
apoptosis proteins
Cells were treated with ZD6474 and/or UV-B and then
the cells were scraped and lysed in Nonidet P-40 lysis buf-
fer (50 mM Tris HCl pH 8.0, 137 mM sodium chloride,
10% glycerol, 1% Nonidet P-40, 50 mM sodium fluoride,
10 mM EDTA) containing 1 mM sodium vanadate, 1 mM
phenylmethylsulfonyl fluoride, and protease cocktail in-
hibitor for obtaining total cell extracts. Equal amount of
cell extracts were separated on a 10% sodium dodecyl
sulfate-polyacrylamide electrophoretic gel (SDS-PAGE)
and transferred to nitrocellulose membranes, which were
blocked with 2% BSA and probed with the appropriate
antibodies and secondary antibodies. Membranes were
then developed using enhanced chemiluminescence or al-
kaline phosphatase-based colorimetric methods.
Caspase-3 and caspase-7 activity assays
Caspase-3 and caspase-7 activity was determined by meas-
uring the absorbance at 405 nm after cleavage of synthetic
substrate acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-
pNA) as described previously [73] with some modifications
[56]. Cells were treated with ZD6474 and/or UV-B radiation
for 48 h, and lysed with buffer (50 mM HEPES, pH 7.4,
5 mM CHAPS, 5 mM DTT, 1 mM PMSF, 20 μg/ml
leupeptin), followed by centrifugation at 20,000 g for 15 min
at 4°C. The lysates (50 μl) were incubated in 200 μM solu-
tion of (Ac-DEVD-pNA) in a reaction buffer (20 mM
HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT)
at 37°C. The reaction was monitored for 1–3 h, and the ab-
sorbance was recorded at 405 nm. If the signal was low, the
reaction can be monitored for 12–24 h. The formation of
pNA was calculated as the difference in the absorbance at
405 nm unit time (min) per unit volume (ml) of sample.
The relative levels of pNA formation were normalizedagainst the protein concentration (mg/ml) of each extract to
obtain specific activity (μmoles pNA/min/mg).
Specific activity ðμ moles pNA=min=mgÞ ¼ ΔO:D
εxt xvxc
Where,
ε = 10.5
v = volume of sample in ml
t = reaction time in minutes
c = concentration of sample in mg/ml
In vitro wounding (scratch) assay
To test the invasive behavior of treated cells, 1 × 105
cells were plated in 6-well tissue culture plates and
grown for 24 h to obtain a confluent monolayer and
migration was studied by in vitro wounding (scratch)
assay [74] with slight modifications. The monolayer was
scraped (wounded) in a straight line to create a “wound
(scratch)” with a p200 pipette tip. The debris were re-
moved and the edge of the wound (scratch) was made
smooth by washing the cells once with 1 ml of the growth
medium and then replaced with 3 ml of complete media
along with ZD6474 and/or UV-B. Cells were observed 48 h
post-treatment. Cells invading the wound (scratch) line were
observed under an inverted phase-contrast microscope
(Leica Microsystems, Wetzlar, Hesse, Germany). The dis-
tances between one sides of the scratch with another were
measured after the indicated time intervals using the Leica
Qwin software. The distance of each wound (scratch) clo-
sure was the measure of wound healing. P-values of wound
size were calculated using un-paired t-test between the same
treatment group, prior and post treatment. Each experiment
was performed three times with triplicate samples.
Scanning electron microscopy (SEM)
Cells were grown in cover slip at a density of 10,000 cells
per cover slip. Cells were treated with ZD6474 and/or UV-
B radiation for 1 day. After that Cells were fixed with 3.7%
Paraformaldehyde (Merck, Mumbai, Mahrashtra, India)
for 30 min, followed by serial dehydration in alcohol (50%,
70%, 75%, 90% , 95% and 100% for 5 min at each step) and
finally subjected in 100 μl 1,1,1,3,3,3-Hexamethyldisilazane
(HMDS) for critical point drying. Samples were then air
dried at room temperature and mounted on stub. Next,
they were placed in vacuum chamber of SEM gold coating
apparatus and gold was coated at 2.5 kV, 20–25 mA for
120 s. The morphogram (surface features) of the MCF-7
and MDA-MB-468 cells were then observed using a JEOL
JSM-5800 Scanning Microscope (Zeol, Peabody, MA,
USA) using 20 kV acceleration voltages.
Immunofluorescence studies
MCF-7 and MDA-MB-468 cells were plated on cover-
slips in DMEM/F-12 complete medium. After 1 day,
Sarkar et al. Molecular Cancer 2013, 12:122 Page 16 of 18
http://www.molecular-cancer.com/content/12/1/122cells were treated with 1 μM ZD6474 and/or 25 J/m2
UV-B for 1 day. Cells were fixed in 3.7% paraformalde-
hyde, and permeabilized with 0.1% Triton-X-100 and
then blocked in 2% BSA, and stained with FITC phal-
loidin to visualize F-actin (Life Technologies, Grand
Island, NY, USA), counterstained with DAPI as per
manufacturer’s instructions. Cells were analyzed by
confocal laser scanning microscopy (CLSM) (Olympus
FluoView FV1000, Version 1.7.1.0) (Olympus, Tokyo,
Japan), using the appropriate wavelength. Images were
captured and digitized using FLUOVIEW 1000 (Version
1.2.4.0) imaging software.
VEGF quantification
Breast cancer cells were treated with ZD6474 and/or
UV-B and incubated in incomplete medium for 48 h.
The conditioned medium (CM) was collected and kept
at −70°C for studying secretory proteins (VEGF, MMPs).
The concentration of VEGF in the serum-free CM
obtained from cultured cells was measured using com-
mercially available sandwich ELISA kits (R&D Systems
Inc., Minneapolis, MN, USA) and according to manufac-
turers’ instructions and the level of VEGF was reported
in ng/ml which is normalized to the number of cells.
Zymography
Activity of matrix metalloprotease-2 (MMP-2) and
matrix metalloprotease-9 (MMP-9) was assessed by ge-
latin Zymography [75]. Briefly, to prepare serum-free
conditioned media (CM), cells were allowed to grow to
subconfluence in 35-mm tissue culture dishes in
DMEM/F-12 containing 10% FBS. After several washes
with serum-free medium, the medium was replaced
with DMEM/F-12 containing ZD6474 after treatment with
UV-B, and the cultures were incubated for an additional
48 h. The conditioned media were collected and applied to
SDS-polyacrylamide gels (7.5% w/v) copolymerized with
gelatin (0.1% w/v) and washed twice in renaturation buffer
(2.5% Triton-X-100) equilibrated in developing buffer
(50 mM Tris-cl pH 8.3, 0.2 M Nacl, 5 mM Cacl2, 0.02%
Brij-35) for initial 30 min at 37°C, followed by incubation
in developing buffer at 37°C for 24 h. Enzyme-digested
regions were quantified by QuantityOne® (Version 4.2.1)
after data acquisition using GS-800™ Calibrated Densi-
tometer (Bio-Rad, Hercules, CA, USA).Additional files
Additional file 1: Figure S1. Influence of ZD6474 on UV-irradiated
breast cancer cells. Photomicrograph of (A) MCF-7 and (B) MDA-MB-468
irradiated with different doses of UV-B and/or 5 μM ZD6474.
Representative data of three independent experiments. Bars, 100 μM.
Additional file 2: Figure S2. Expression of Nuclear excision repair (NER)
protein in breast cancer cells. Breast cancer cells were collected andwhole cell lysates were prepared, protein was separated by SDS-PAGE
and western blotting of indicated protein was performed. β-actin was
used as loading control.
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